Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Ernesto Iacucci et al.|Cancer Discovery|2020Cited by 239
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.Arlene O. Siefker‐Radtke, Mehmet Asım Bilen, Mayer Fishman et al.|Journal of Clinical Oncology|2019Cited by 22
PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.Daniel A. Vaena, James K. Schwarz, Jorge Chaves et al.|Journal of Clinical Oncology|2018Cited by 3
Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0